$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000090670920000009 Filed on May 08, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$50.57M	$28.22M
YoY Change	79.2%	-25.77%
Cost Of Revenue	$3.811M	$5.440M
YoY Change	-29.94%	-18.15%
Gross Profit	$46.76M	$22.78M
YoY Change	105.26%	-27.38%
Gross Profit Margin	92.46%	80.72%
Selling, General & Admin	$26.20M	$25.00M
YoY Change	4.8%	33.69%
% of Gross Profit	56.03%	109.74%
Research & Development	$109.0M	$118.5M
YoY Change	-8.0%	19.15%
% of Gross Profit	233.07%	519.99%
Depreciation & Amortization	$4.500M	$3.100M
YoY Change	45.16%	24.0%
% of Gross Profit	9.62%	13.61%
Operating Expenses	$109.0M	$118.5M
YoY Change	-8.0%	19.15%
Operating Profit	-$133.6M	-$120.7M
YoY Change	10.73%	39.14%
Interest Expense	$6.204M	$5.226M
YoY Change	18.71%	-2.13%
% of Operating Profit
Other Income/Expense, Net	-$4.820M	$1.192M
YoY Change	-504.36%	-113.56%
Pretax Income	-$138.5M	-$119.5M
YoY Change	15.86%	25.09%
Income Tax	$200.0K	$137.0K
% Of Pretax Income
Net Earnings	-$138.7M	-$119.6M
YoY Change	15.9%	24.89%
Net Earnings / Revenue	-274.16%	-423.9%
Basic Earnings Per Share	-$0.78	-$0.69
Diluted Earnings Per Share	-$0.78	-$0.69
COMMON SHARES
Basic Shares Outstanding	177.6M shares	174.1M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.346B	$1.389B
YoY Change	-3.08%	368.05%
Cash & Equivalents	$227.0M	$106.8M
Short-Term Investments	$1.119B	$1.282B
Other Short-Term Assets	$13.81M	$46.80M
YoY Change	-70.49%	257.25%
Inventory	$14.32M	$11.80M
Prepaid Expenses
Receivables	$42.03M	$42.90M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.429B	$1.490B
YoY Change	-4.08%	343.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.31M	$141.6M
YoY Change	-56.0%	205.83%
Goodwill	$76.50M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$185.9M	$455.9M
YoY Change	-59.22%	1125.54%
Other Assets		$2.400M
YoY Change		200.0%
Total Long-Term Assets	$458.6M	$676.4M
YoY Change	-32.2%	320.65%
TOTAL ASSETS
Total Short-Term Assets	$1.429B	$1.490B
Total Long-Term Assets	$458.6M	$676.4M
Total Assets	$1.888B	$2.167B
YoY Change	-12.86%	336.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$21.79M	$11.00M
YoY Change	98.08%	-3.51%
Accrued Expenses	$97.10M	$77.60M
YoY Change	25.13%	56.14%
Deferred Revenue	$3.007M	$11.09M
YoY Change	-72.89%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$254.1M
YoY Change
Total Short-Term Liabilities	$377.5M	$99.70M
YoY Change	278.61%	23.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$247.4M
YoY Change	-100.0%	0.73%
Other Long-Term Liabilities	$214.0M	$185.9M
YoY Change	15.12%	65.69%
Total Long-Term Liabilities	$214.0M	$433.3M
YoY Change	-50.61%	21.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$377.5M	$99.70M
Total Long-Term Liabilities	$214.0M	$433.3M
Total Liabilities	$591.5M	$533.0M
YoY Change	10.98%	21.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.003B
YoY Change
Common Stock	$3.307B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.296B	$1.634B
YoY Change
Total Liabilities & Shareholders Equity	$1.888B	$2.167B
YoY Change	-12.86%	336.09%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$138.7M	-$119.6M
YoY Change	15.9%	24.89%
Depreciation, Depletion And Amortization	$4.500M	$3.100M
YoY Change	45.16%	24.0%
Cash From Operating Activities	-$78.08M	-$80.90M
YoY Change	-3.49%	54.19%
INVESTING ACTIVITIES
Capital Expenditures	$900.0K	$5.648M
YoY Change	-84.07%	473.4%
Acquisitions
YoY Change
Other Investing Activities	$198.7M	-$6.500M
YoY Change	-3156.92%	-113.21%
Cash From Investing Activities	$197.8M	-$12.14M
YoY Change	-1729.32%	-125.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$11.08M	$4.894M
YoY Change	126.34%	-85.75%
NET CHANGE
Cash From Operating Activities	-$78.08M	-$80.90M
Cash From Investing Activities	$197.8M	-$12.14M
Cash From Financing Activities	$11.08M	$4.894M
Net Change In Cash	$130.7M	-$88.15M
YoY Change	-248.23%	-393.42%
FREE CASH FLOW
Cash From Operating Activities	-$78.08M	-$80.90M
Capital Expenditures	$900.0K	$5.648M
Free Cash Flow	-$78.98M	-$86.54M
YoY Change	-8.74%	61.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2020Q1	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177863000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	176505000	shares
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	0-24006
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
CY2020Q1	dei	City Area Code CityAreaCode	415
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	482-5300
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2020Q1	dei	Trading Symbol TradingSymbol	NKTR
CY2019Q4	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	31834000	USD
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	177989857	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227035000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1118847000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	42031000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	36802000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	14320000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
CY2020Q1	nktr	Advance Payments To Contract Manufacturers AdvancePaymentsToContractManufacturers	13280000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	13811000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	15731000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	1429324000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1421894000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	185900000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62307000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65665000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	133901000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	134177000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	76501000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	76501000	USD
CY2020Q1	us-gaap	Assets Assets	1887933000	USD
CY2019Q4	us-gaap	Assets Assets	1977356000	USD
CY2020Q1	us-gaap	Senior Notes Current SeniorNotesCurrent	254144000	USD
CY2019Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	252891000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	21789000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	19234000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22412000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11467000	USD
CY2020Q1	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	38624000	USD
CY2019Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	32626000	USD
CY2020Q1	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	8579000	USD
CY2019Q4	nktr	Accrued Contract Manufacturing Expense Current AccruedContractManufacturingExpenseCurrent	7304000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11844000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	11414000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	15613000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12516000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3007000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5517000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1459000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1692000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	377471000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	354661000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	142297000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	142730000	USD
CY2020Q1	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	69185000	USD
CY2019Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	72020000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2554000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2554000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	591507000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	571965000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2020Q1	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	177863000	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	17000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3306655000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3271097000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6877000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1005000	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	184204000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2003369000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1864718000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1296426000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1887933000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1977356000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	50573000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28222000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3811000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5440000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	108987000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	118463000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26217000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25006000	USD
CY2020Q1	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	45189000	USD
CY2019Q1	nktr	Impairment Of Equipment And Other Costs For Terminated Program ImpairmentOfEquipmentAndOtherCostsForTerminatedProgram	0	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	148909000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-133631000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-120687000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	6204000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	5226000	USD
CY2020Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6968000	USD
CY2019Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6065000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8352000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12483000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4820000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1192000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-138451000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-119495000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	200000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	137000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5463000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-119632000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	177185000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	173859000	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-138651000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-119632000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5121000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4685000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-751000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	35000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5872000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4720000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114912000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1717575000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25385000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114912000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1633511000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1405391000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11347000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24211000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144523000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1296426000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-138651000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-119632000	USD
CY2020Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	9895000	USD
CY2019Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	8230000	USD
CY2020Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6968000	USD
CY2019Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6065000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25236000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25385000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4502000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3077000	USD
CY2020Q1	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	20351000	USD
CY2019Q1	nktr	Impairment Of Equipment From Terminated Program ImpairmentOfEquipmentFromTerminatedProgram	0	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1289000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3183000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5229000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-319000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1655000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	397000	USD
CY2020Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2940000	USD
CY2019Q1	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-1168000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1067000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4209000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2687000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5156000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	9920000	USD
CY2019Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	8434000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7716000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	774000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2510000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4204000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-233000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	164000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78075000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-80895000	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	241068000	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	368739000	USD
CY2020Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	439735000	USD
CY2019Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	362249000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	900000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5648000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	197767000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12138000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	11077000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	4894000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11077000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4894000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-97000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	130672000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-88153000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96363000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194905000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227035000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106752000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	4951000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	4805000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2133000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1289000	USD
CY2020Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1500000000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We consider the effects of the COVID-19 pandemic in developing our estimates.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess our estimates each period, update them to reflect current information and generally recognize any changes in such estimates in the period first identified.</span></div>
CY2020Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassifications</span></div><div style="text-indent:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12). ASU 2019-12 created an exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items (for example, discontinued operations or other comprehensive income). Under the historical guidance, in this situation, an entity would record an income tax provision from other items, such as unrealized gains on available-for-sale securities reported in other comprehensive income, with an offsetting income tax benefit in continuing operations. Under ASU 2019-12, an entity would record no income tax provision. We elected to adopt ASU 2019-12 effective January 1, 2019 on a prospective basis in accordance with the guidance. Because we reported a net loss and unrealized gains on available-for-sale securities during 2019 and accordingly recorded a tax provision pursuant to the legacy guidance, we have recast such results from previously reported amounts. As a result, we eliminated the tax benefit in continuing operations and tax provision in other comprehensive income (loss), which totaled $1.1 million for the three months ended March 31, 2019. </span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation. Such reclassifications do not materially impact previously reported revenue, operating loss, net loss, total assets, liabilities or stockholders’ equity.</span></div>
CY2019Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	1100000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Significant Concentrations</span></div><div style="text-indent:31.5pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones, other contingent payments and royalties, as well as reimbursable costs from collaborative research and development agreements. As of March 31, 2020, our accounts receivable includes $10.9 million under customer contracts from our collaboration partners and $31.2 million for unbilled net expense reimbursements from our collaboration partner Bristol-Myers Squibb Company (BMS). As of December 31, 2019, our accounts receivable included $12.8 million from customer contracts and $24.0 million for unbilled net expense reimbursements from BMS. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have not experienced credit losses from our accounts receivable. We have not recorded a reserve for credit losses at March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:31.5pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services, automotive and food and beverage industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic may materially affect the financial conditions of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been </span></div>downgraded below our minimum credit rating requirements, which may result in a loss on the sale. As a result of the COVID-19 pandemic, we have begun to see an increase in credit downgrades for certain of our securities. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6500000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227035000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96363000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1118847000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1228499000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	185900000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	279119000	USD
CY2020Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1531782000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
CY2020Q1	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
CY2020Q1	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q1	us-gaap	Senior Notes SeniorNotes	254800000	USD
CY2020Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	6200000	USD
CY2020Q1	us-gaap	Cash Cash	5994000	USD
CY2019Q4	us-gaap	Cash Cash	5829000	USD
CY2020Q1	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1531782000	USD
CY2019Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	1603981000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2100000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	300000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1198000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1673000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11463000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8267000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1659000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2725000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	14320000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	12665000	USD
CY2020Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	9900000	USD
CY2019Q1	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	8200000	USD
CY2020Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	7000000.0	USD
CY2019Q1	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	6100000	USD
	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.17
CY2017Q4	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.176
CY2017Q4	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.21
CY2018Q4	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.187
CY2018Q4	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.29
CY2019Q4	nktr	Estimated Annual Interest Rate Over Life Of Royalty Liability EstimatedAnnualInterestRateOverLifeOfRoyaltyLiability	0.195
CY2019Q4	nktr	Prospective Interest Rate Percentage ProspectiveInterestRatePercentage	0.38
CY2020Q1	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	27515000	USD
CY2019Q1	nktr	License Collaboration Other Revenue LicenseCollaborationOtherRevenue	4204000	USD
CY2020Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	44600000	USD
CY2019Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	19600000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8071000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2510000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5561000	USD
CY2020Q1	nktr	Potential Development And Regulatory Milestones PotentialDevelopmentAndRegulatoryMilestones	1700000000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25236000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25385000	USD
CY2020Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	49000	shares
CY2019Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	20000	shares

Files In Submission

Name	View Source	Status
0000906709-20-000009-index-headers.html	Edgar Link	pending
0000906709-20-000009-index.html	Edgar Link	pending
0000906709-20-000009.txt	Edgar Link	pending
0000906709-20-000009-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20200331.htm	Edgar Link	pending
nktr-20200331.xsd	Edgar Link	pending
nktr-20200331_cal.xml	Edgar Link	unprocessable
nktr-20200331_def.xml	Edgar Link	unprocessable
nktr-20200331_htm.xml	Edgar Link	completed
nktr-20200331_lab.xml	Edgar Link	unprocessable
nktr-20200331_pre.xml	Edgar Link	unprocessable
nktr2020-03x31ex101.htm	Edgar Link	pending
nktr2020-03x31xexx311.htm	Edgar Link	pending
nktr2020-03x31xexx312.htm	Edgar Link	pending
nktr2020-03x31xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2020 Q1 Form 10-Q Financial Statement

#000090670920000009 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2020 Q1 Form 10-Q Financial Statement

#000090670920000009 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr